Congress
$1,001–$15,000
Traded Feb 12 · disclosed 28 days later
3 different filers disclosed REGN within 90 days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 9, 2026 · Filed Feb 11, 2026
Regeneron Pharmaceuticals's SVP Controller sold $16K of Regeneron Pharmaceuticals shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$15,519
Shares × reported transaction price
10 days after results of Jan 30, 2026, 58 days before results of Apr 8, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $780.28 on Feb 9, 2026, within 4% of its 52-week high, little changed over the previous 30 trading days
52-week range $483.07 (Jun 5, 2025) to $812.27 (Jan 7, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $783.71 on Dec 24, 2025. Describes the past only, not a forecast
RSI 57, 25% above its 200-day average, 3% above its 50-day average, 4% below the 52-week high, 20-day volatility 26% a year, against the S&P 500: −3 points over 1 month, +17 points over 3 months, +30 points over 6 months
From the adjusted closes up to Feb 9, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Dupixent on Feb 23, 2026, 14 days after this trade.
New use approved (efficacy supplement). Active ingredient: Dupilumab. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.2% | +0.5% | −0.6% |
| 30 days | −3.4% | −1.8% | −1.6% |
| 90 days | −8.1% | +9.0% | −17.1% |
| 180 days | +1.7% | +13.1% | −11.4% |
Past results only. Not a forecast.
Congress
Traded Feb 12 · disclosed 28 days later
3 different filers disclosed REGN within 90 days.
Arthur F Ryan (Director) sold ~$5.4K of Regeneron Pharmaceuticals
Planned saleArthur F Ryan (Director) sold ~$1.6K of Regeneron Pharmaceuticals
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.